

**Drugs and Therapeutics (D & T) Committee  
Meeting Results  
January 12, 2023**

<b>Drug Name</b>	<b>Review Type</b>	<b>Committee Recommendation</b>	<b>Preferred Status – Final Determination</b>
Adbry	New Drug Initial Review	Non-Preferred	Non-Preferred
Hyftor	New Drug Initial Review	Non-Preferred	Non-Preferred
Ztalmy	New Drug Appeal	Non-Preferred	Non-Preferred

**Tardive Dyskinesia  
Class Review Results**

Austedo		Preferred with PA	
Xenazine			Non-Preferred
Tetrabenazine			Non-Preferred
Ingrezza		Preferred with PA	

**Hereditary Angioedema  
Class Review Results**

<b>Hereditary Angioedema Class Review Results</b>			
Berinert		Preferred with PA	
Ruconest			Non-Preferred
Firazyr			Non-Preferred
Icatibant			Non-Preferred
Sajazir			Non-Preferred
Kalbitor			Non-Preferred
Cinryze			Non-Preferred
Haegarda			Non-Preferred
Orladeyo			Non-Preferred
Takhzyro			Non-Preferred